Mincyclin reduces secondary nerve degeneration

Back to overview

Numerous preclinical studies have shown that the compound minocycline had a neuroprotective effect, reducing the extent of progressive tissue loss.

The University of Calgary initiated a “randomized controlled clinical trial” (RCT) treating patients with acute spinal cord injury and started recruiting patients in 2004.

More information here